Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
click here now to get all the chilling details.
Robert Alan Schueren net worth and biography

Robert Schueren Biography and Net Worth

COO of Natera
Robert A. Schueren is Chief Operating Officer of the Company. Mr. Schueren served as chief executive officer and president of IntegenX Inc., a biotechnology company, from March 2013 to January 2019. Mr. Schueren served as vice president and general manager of the Genomics Solutions division at Agilent Technologies Inc. from January 2010 to January 2013; and prior to that, Mr. Schueren served at various companies including Genentech, Inc. and Arcturus Bioscience. Mr. Schueren holds a Bachelor of Science in Pharmacy from Temple University.

What is Robert Alan Schueren's net worth?

The estimated net worth of Robert Alan Schueren is at least $184,845.24 as of January 23rd, 2023. Mr. Schueren owns 4,226 shares of Natera stock worth more than $184,845 as of January 28th. This net worth approximation does not reflect any other assets that Mr. Schueren may own. Additionally, Mr. Schueren receives an annual salary of $706,720.00 as COO at Natera. Learn More about Robert Alan Schueren's net worth.

How old is Robert Alan Schueren?

Mr. Schueren is currently 61 years old. There are 5 older executives and no younger executives at Natera. Learn More on Robert Alan Schueren's age.

What is Robert Alan Schueren's salary?

As the COO of Natera, Inc., Mr. Schueren earned a total compensation package of $9,802,919.00 in 2021. Mr. Schueren earned a salary of $464,756.00, stock awards of $9,096,200.00, non-equity compensation of $233,263.00, and other compensation of $8,700.00.The highest earning executive at Natera is Mr. Steven Leonard Chapman, CEO, Pres & Director, who commands a salary of $925,590.00 per year. Learn More on Robert Alan Schueren's salary.

How do I contact Robert Alan Schueren?

The corporate mailing address for Mr. Schueren and other Natera executives is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. Natera can also be reached via phone at (650) 249-9090 and via email at [email protected] Learn More on Robert Alan Schueren's contact information.

Has Robert Alan Schueren been buying or selling shares of Natera?

In the last ninety days, Robert Alan Schueren has sold $453,353.44 of Natera stock. Most recently, Robert Alan Schueren sold 4,256 shares of the business's stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $41.56, for a transaction totalling $176,879.36. Following the completion of the sale, the chief operating officer now directly owns 4,226 shares of the company's stock, valued at $175,632.56. Learn More on Robert Alan Schueren's trading history.

Who are Natera's active insiders?

Natera's insider roster includes Roy Baynes (Director), Roelof Botha (Director), Michael Brophy (CFO), Rowan Chapman (Director), Steven Chapman (CEO), Todd Cozzens (Director), James Healy (Director), Gail Marcus (Director), Daniel Rabinowitz (Insider), Matthew Rabinowitz (Chairman), Herm Rosenman (Director), Robert Schueren (COO), and Jonathan Sheena (Insider). Learn More on Natera's active insiders.

Are insiders buying or selling shares of Natera?

During the last twelve months, Natera insiders bought shares 2 times. They purchased a total of 372,820 shares worth more than $11,323,786.80. During the last twelve months, insiders at the medical research company sold shares 60 times. They sold a total of 96,087 shares worth more than $3,913,739.28. The most recent insider tranaction occured on January, 23rd when insider Daniel Rabinowitz sold 2,387 shares worth more than $99,203.72. Insiders at Natera own 10.3% of the company. Learn More about insider trades at Natera.

Information on this page was last updated on 1/23/2023.

Robert Alan Schueren Insider Trading History at Natera

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/23/2023Sell4,256$41.56$176,879.364,226View SEC Filing Icon  
1/9/2023Sell2,244$37.62$84,419.287,886View SEC Filing Icon  
1/3/2023Sell4,856$39.55$192,054.806,145View SEC Filing Icon  
12/28/2022Sell1,382$39.84$55,058.881,367View SEC Filing Icon  
10/24/2022Sell3,135$42.41$132,955.354,932View SEC Filing Icon  
10/10/2022Sell2,008$42.12$84,576.963,915View SEC Filing Icon  
9/28/2022Sell1,382$44.04$60,863.281,939View SEC Filing Icon  
7/22/2022Sell572$46.26$26,460.72572View SEC Filing Icon  
7/8/2022Sell2,019$39.51$79,770.693,326View SEC Filing Icon  
6/28/2022Sell1,390$39.02$54,237.801,360View SEC Filing Icon  
4/22/2022Sell577$36.14$20,852.783,919View SEC Filing Icon  
4/8/2022Sell1,999$41.91$83,778.093,352View SEC Filing Icon  
3/28/2022Sell1,382$39.63$54,768.66View SEC Filing Icon  
1/24/2022Sell2,378$59.95$142,561.10View SEC Filing Icon  
1/10/2022Sell2,116$74.45$157,536.20View SEC Filing Icon  
12/28/2021Sell1,382$91.34$126,231.88View SEC Filing Icon  
12/21/2021Sell5,000$92.97$464,850.00View SEC Filing Icon  
12/7/2021Sell4,411$91.99$405,767.89View SEC Filing Icon  
11/1/2021Sell12,000$120.00$1,440,000.00View SEC Filing Icon  
10/8/2021Sell1,986$117.08$232,520.88View SEC Filing Icon  
9/28/2021Sell1,431$109.71$156,995.01View SEC Filing Icon  
9/10/2021Sell6,278$119.53$750,409.34View SEC Filing Icon  
7/8/2021Sell2,032$113.34$230,306.88View SEC Filing Icon  
6/28/2021Sell1,381$117.57$162,364.17View SEC Filing Icon  
6/8/2021Sell12,073$105.21$1,270,200.3326,252View SEC Filing Icon  
6/4/2021Sell4,395$97.51$428,556.45View SEC Filing Icon  
4/13/2021Sell22,093$104.21$2,302,311.5350,972View SEC Filing Icon  
4/9/2021Sell1,912$104.86$200,492.328,894View SEC Filing Icon  
3/29/2021Sell6,088$83.94$511,026.7210,997View SEC Filing Icon  
3/10/2021Sell6,327$97.33$615,806.91View SEC Filing Icon  
1/8/2021Sell2,066$109.32$225,855.1253,340View SEC Filing Icon  
12/22/2020Sell5,999$105.48$632,774.5255,355View SEC Filing Icon  
12/14/2020Sell20,000$100.67$2,013,400.0062,855View SEC Filing Icon  
10/8/2020Sell1,987$74.26$147,554.6254,842View SEC Filing Icon  
9/25/2020Sell20,000$70.00$1,400,000.0070,857View SEC Filing Icon  
9/4/2020Sell9,072$61.56$558,472.3259,929View SEC Filing Icon  
7/8/2020Sell1,987$47.00$93,389.0044,416View SEC Filing Icon  
7/1/2020Sell15,000$50.00$750,000.0055,432View SEC Filing Icon  
6/24/2020Sell6,362$45.47$289,280.1446,794View SEC Filing Icon  
6/9/2020Sell12,927$42.38$547,846.2647,221View SEC Filing Icon  
5/7/2020Sell15,000$40.00$600,000.0037,221View SEC Filing Icon  
4/8/2020Sell1,988$30.21$60,057.4824,209View SEC Filing Icon  
1/8/2020Sell8,167$34.99$285,763.3328,392View SEC Filing Icon  
9/20/2019Sell12,545$33.19$416,368.5525,000View SEC Filing Icon  
See Full Table

Robert Alan Schueren Buying and Selling Activity at Natera

This chart shows Robert Alan Schueren's buying and selling at Natera by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Natera Company Overview

Natera logo
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
Read More

Today's Range

Now: $43.74
Low: $41.89
High: $44.21

50 Day Range

MA: $39.96
Low: $35.29
High: $43.74

2 Week Range

Now: $43.74
Low: $26.10
High: $74.82


659,164 shs

Average Volume

1,300,920 shs

Market Capitalization

$4.27 billion

P/E Ratio


Dividend Yield



The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Click here to watch it, free.